Repligen Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US7599161095
USD
163.90
4.46 (2.8%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Incyte Corp.
Alnylam Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc.
Viatris, Inc.
United Therapeutics Corp.
Repligen Corp.
Royalty Pharma Plc
Sarepta Therapeutics, Inc.
Walgreens Boots Alliance, Inc.
Horizon Therapeutics Plc
Seagen Inc.

Why is Repligen Corp. ?

1
Poor Management Efficiency with a low ROE of 5.44%
  • The company has been able to generate a Return on Equity (avg) of 5.44% signifying low profitability per unit of shareholders funds
2
The company is Net-Debt Free
3
Healthy long term growth as Net Sales has grown by an annual rate of 15.05% and Operating profit at -7.64%
4
Flat results in Jun 26
  • OPERATING PROFIT MARGIN(Q) Lowest at 21.62 %
  • NET PROFIT(Q) Lowest at USD 7 MM
  • EPS(Q) Lowest at USD 0.09
5
With ROE of 2.15%, it has a fair valuation with a 2.95 Price to Book Value
  • The stock is trading at a premium compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 44.38%, its profits have risen by 40.1% ; the PEG ratio of the company is 3.5
6
High Institutional Holdings at 100%
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
7
Market Beating Performance
  • The stock has generated a return of 44.38% in the last 1 year, much higher than market (S&P 500) returns of 22.36%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Repligen Corp. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Repligen Corp. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Repligen Corp.
44.38%
0.33
47.99%
S&P 500
22.36%
1.70
13.18%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
15.05%
EBIT Growth (5y)
-7.64%
EBIT to Interest (avg)
20.41
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.08
Sales to Capital Employed (avg)
0.26
Tax Ratio
0.85%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
7.81%
ROE (avg)
5.44%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
137
Industry P/E
Price to Book Value
2.95
EV to EBIT
117.86
EV to EBITDA
33.86
EV to Capital Employed
3.15
EV to Sales
8.13
PEG Ratio
3.47
Dividend Yield
NA
ROCE (Latest)
2.68%
ROE (Latest)
2.15%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company
RAW MATERIAL COST(Y)

Fallen by -8.79% (YoY

CASH AND EQV(HY)

Highest at USD 1,594.98 MM

DEBT-EQUITY RATIO (HY)

Lowest at -5.66 %

NET SALES(Q)

Highest at USD 204.13 MM

PRE-TAX PROFIT(Q)

At USD 19.78 MM has Grown at 53.67%

-6What is not working for the Company
OPERATING PROFIT MARGIN(Q)

Lowest at 21.62 %

NET PROFIT(Q)

Lowest at USD 7 MM

EPS(Q)

Lowest at USD 0.09

Here's what is working for Repligen Corp.

Net Sales
Highest at USD 204.13 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (USD MM)

Pre-Tax Profit
At USD 19.78 MM has Grown at 53.67%
over average net sales of the previous four periods of USD 12.87 MM
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Cash and Eqv
Highest at USD 1,594.98 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio
Lowest at -5.66 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost
Fallen by -8.79% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Repligen Corp.

Net Profit
At USD 7 MM has Fallen at -41.36%
over average net sales of the previous four periods of USD 11.93 MM
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Profit Margin
Lowest at 21.62 %
in the last five periods
MOJO Watch
Company's profit margin has deteriorated

Operating Profit to Sales

Net Profit
Lowest at USD 7 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is negative

Net Profit (USD MM)

EPS
Lowest at USD 0.09
in the last five periods
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (USD)